CClinicalTrials.gg
CompletedNCT01671358Updated Jun 2, 2015

Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms

An observational study in Methicillin-Resistant Staphylococcus Aureus, sponsored by West Virginia University. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2015-06-02.

Sponsored by West Virginia University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Sex
All
01

Study summary

This study is to determine if medication cabinets located outside of isolation rooms in hospitals and their contents, particularly medications and the delivery folders are at a higher risk of having harmful bacteria on them.

Read the detailed description

Studies show high touch areas maybe contaminated with organisms such as Methicillin-resistant Staphylococcus aureus(MRSA) and vancomycin-resistant enterococci. MRSA can live on hospital surfaces for 9-14 days. Patients in rooms that were previously MRSA isolation rooms are at higher risk for developing a hospital-acquired infection.

This study is to determine if medication cabinets located outside of MRSA isolation rooms and their contents, particularly medications and the pharmacy delivery folders are at a higher risk of having MRSA colonization on them. This study will use conventional methods to determine if MRSA colonization is present and compare results between non-isolation and isolation rooms. This will evaluate if alternate measures for the reduction of MRSA colonization are needed for the MRSA isolation rooms in regards to medication delivery and storage.

02

Conditions studied

  • Methicillin-Resistant Staphylococcus Aureus

Keywords

  • MRSA
  • Contamination
  • Isolation
03

In context

Staphylococcal Infections

273 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.

This study's enrollment of 400 is above the median of 200 across 81 observational studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

West Virginia University is the lead sponsor of 155 studies on the registry; 35 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Inaptients at an academic medical center

Inclusion criteria

  • Patient rooms with isolation status for MRSA
  • Patient rooms without isolation status for MRSA for 14 days

Exclusion criteria

Exclusion Criteria:

  • Rooms without medication cabinets directly outside the room
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (actual)

Groups and cohorts

  • Isolation Rooms for MRSA

    Rooms that currently have a patient in them that are in isolation status due to MRSA

  • Non-isolation rooms

    Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days

06

What researchers measure

Primary outcomes

  1. Presence of MRSA colonization

    Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. Individual colonies will be removed from the plate with an inoculation loop, then streaked onto a second sheep blood agar plate. The second plates will be incubated for 48 hours. The colonies will then be run through standard identification tests to determine if the colonies are MRSA or not. A comparison will be made between non-isolation and isolation rooms.

    Time frame: Hospital stay, an expected average of 14 days

Secondary outcomes

  1. Quantification of MRSA colonization

    Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. A comparison between the sites of swabbing will be performed.

    Time frame: Hospital stay, an expected average of 14 days

Other outcomes

  1. Presence of other bacterial colonization

    Swabbing of four areas of the medication cabinet will be performed (keypad, handle, medication folder and a medication). A Semi-quantitative sampling technique will be used to collect the samples. A sterile saline moistened sterile cotton tip swab will be used to swab the specified areas. The swabs will then be used to inoculate sheep blood agar plates in 4 quadrants. The plates will be incubated for 48 hours. The number of quadrants with growth will be identified. Individual colonies will be removed from the plate with an inoculation loop, then streaked onto a second sheep blood agar plate. The second plates will be incubated for 48 hours. The colonies will be categorized as gram negative, gram positive catalase negative, Gram positive coagulase negative Staphylococcus species or methicillin-sensitive Staphylococcus aureus. This will serve as a baseline epidemiology of the hospital and generate other possible hypotheses.

    Time frame: Hospital stay, an expected average of 14 days

  2. Correlation between MRSA and active infection or colonization of patient

    The patient from the same time frame in the rooms sampled and positive for MRSA colonization will be reviewed to determine if they had active infection or were previously colonized.

    Time frame: Hospital stay, an expected average of 14 days

  3. Correlation between colonization of other positive organisms and active infection or colonization of patient

    The patient from the same time frame in the rooms sampled and positive for non-MRSA colonization will be reviewed to determine if they had active infection or were previously colonized.

    Time frame: Hospital stay, an expected average of 14 days

07

Study locations

1 site
  • West Virginia University Hospitals
    Morgantown, West Virginia 26506, United States
08

References and documents

Publications

  • Bures S, Fishbain JT, Uyehara CF, Parker JM, Berg BW. Computer keyboards and faucet handles as reservoirs of nosocomial pathogens in the intensive care unit. Am J Infect Control. 2000 Dec;28(6):465-71. doi: 10.1067/mic.2000.107267. PubMed 11114617 ↗
  • Sexton T, Clarke P, O'Neill E, Dillane T, Humphreys H. Environmental reservoirs of methicillin-resistant Staphylococcus aureus in isolation rooms: correlation with patient isolates and implications for hospital hygiene. J Hosp Infect. 2006 Feb;62(2):187-94. doi: 10.1016/j.jhin.2005.07.017. Epub 2005 Nov 14. PubMed 16290319 ↗
  • Oie S, Hosokawa I, Kamiya A. Contamination of room door handles by methicillin-sensitive/methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2002 Jun;51(2):140-3. doi: 10.1053/jhin.2002.1221. PubMed 12090803 ↗
  • Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch Intern Med. 2006 Oct 9;166(18):1945-51. doi: 10.1001/archinte.166.18.1945. PubMed 17030826 ↗
  • Huang R, Mehta S, Weed D, Price CS. Methicillin-resistant Staphylococcus aureus survival on hospital fomites. Infect Control Hosp Epidemiol. 2006 Nov;27(11):1267-9. doi: 10.1086/507965. Epub 2006 Sep 28. PubMed 17080391 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01671358
Lead sponsor
West Virginia University
Responsible party
Michael Sweet (Pharmacy Clinical Specialist - Quality Outcomes, West Virginia University) — Principal investigator
First posted
Aug 23, 2012
Start date
Aug 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jun 2, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion